COVID-19 Vaccines

Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19.

Also Known As:

2019 nCoV Vaccine; 2019 nCoV Vaccines; COVID 19 Vaccines; COVID 19 Virus Vaccine; COVID 19 Virus Vaccines; Coronavirus Disease 19 Vaccine; Coronavirus Disease 19 Vaccines; SARS CoV 2 Vaccine; SARS CoV 2 Vaccines; Vaccine, 2019-nCoV; Vaccine, COVID 19; Vaccine, COVID-19; Vaccine, COVID-19 Virus; Vaccine, COVID19; Vaccine, COVID19 Virus; Vaccine, Coronavirus Disease-19; Vaccine, SARS-CoV-2; Vaccine, SARS2; Vaccines, 2019-nCoV; Vaccines, COVID-19; Vaccines, COVID-19 Virus; Vaccines, COVID19; Vaccines, COVID19 Virus; Vaccines, Coronavirus Disease-19; Vaccines, SARS-CoV-2; Vaccines, SARS2; Virus Vaccine, COVID-19; Virus Vaccine, COVID19; Virus Vaccines, COVID-19; Virus Vaccines, COVID19; 2019 Novel Coronavirus Vaccine; 2019 Novel Coronavirus Vaccines; 2019-nCoV Vaccine; 2019-nCoV Vaccines; COVID 19 Vaccine; COVID-19 Vaccine; COVID-19 Virus Vaccine; COVID-19 Virus Vaccines; COVID19 Vaccine; COVID19 Vaccines; COVID19 Virus Vaccine; COVID19 Virus Vaccines; Coronavirus Disease 2019 Vaccine; Coronavirus Disease 2019 Vaccines; Coronavirus Disease 2019 Virus Vaccine; Coronavirus Disease 2019 Virus Vaccines; Coronavirus Disease-19 Vaccine; Coronavirus Disease-19 Vaccines; SARS Coronavirus 2 Vaccines; SARS-CoV-2 Vaccine; SARS-CoV-2 Vaccines; SARS2 Vaccine; SARS2 Vaccines

Networked: 7607 relevant articles (497 outcomes, 1069 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Viral Vaccines: 462
      - COVID-19 Vaccines: 7607
        BNT162 Vaccine: 2727
        ChAdOx1 nCoV-19: 924
        2019-nCoV Vaccine mRNA-1273: 858
        sinovac COVID-19 vaccine: 399
        Ad26COVS1: 264
        BIBP COVID-19 vaccine: 129
        BBV152 COVID-19 vaccine: 90
        COVID-19 vaccine booster shot: 68
        NVX-CoV2373 adjuvated lipid nanoparticle: 53
        ZF2001 COVID-19 vaccine: 18
        Gam-COVID-Vac vaccine: 15
        COH04S1 COVID-19 vaccine: 7
        SCB-2019 COVID-19 vaccine: 7
        reluscovtogene ralaplasmid: 6
        Ad5-nCoV vaccine: 5
        Corbevax COVID-19 vaccine: 4
        COVI-VAC: 4
        EpiVacCorona vaccine: 4
        CoraVax COVID-19 vaccine: 3
        HIPRA COVID-19 vaccine: 3
        mRNA-1273.214 COVID-19 vaccine: 3
        MVC-COV1901 vaccine: 3
        SCTV01C vaccine: 3
        AKS-452 COVID-19 vaccine: 2
        Baiya SARS-CoV-2 VAX COVID-19 vaccine: 2
        COVAC-1 COVID-19 vaccine: 2
        GX-19N vaccine: 2
        heterologous prime boost COVID-19 vaccination: 2
        RQ3013 COVID-19 vaccine: 2
        TURKOVAC: 2
        UB-612 COVID-19 vaccine: 2
        ACM-001 COVID-19 vaccine: 1
        ChulaCov19 vaccine: 1
        CV0501 COVID-19 vaccine: 1
        CVXGA1 COVID-19 vaccine: 1
        GBP510 vaccine: 1
        GLS-5310 vaccine: 1
        NDV-HXP-S COVID-19 vaccine: 1
        PTX-COVID19-B COVID-19 vaccine: 1
        S-268019-b COVID-19 vaccine: 1
        SARS-CoV-2 inactivated vaccines: 1
        ABNCoV2 vaccine
        AdCLD-CoV19-1 vaccine
        ARCT-154 vaccine
        AV-COVID-19 vaccine
        BNT162b5
        COVAC1 vaccine
        Covid-19 aAPC vaccine
        COVID-19 nanoparticle vaccine
        CVnCoV COVID-19 vaccine
        famtozinameran
        GRT-R910 vaccine
        lentiviral minigene vaccine of COVID-19 coronavirus
        LVRNA009 COVID-19 vaccine
        mRNA-1073 COVID-19 and influenza combined vaccine
        MRT5500 vaccine
        MT-2766 vaccine
        NRC-VACC-101 vaccine
        PittCoVacc
        PRIME-2-CoV_Beta COVID-19 vaccine
        repRNA-CoV2S vaccine
        RVM-V001 COVID-19 vaccine
        rVSV-deltaG-spike COVID-19 vaccine
        SARS-CoV-2 recombinant spike protein with delta inulin and CpG-ODN adjuvant vaccine
        Spikevax bivalent zero omicron
        SYS6006 COVID-19 vaccine
        vaksin merah putih - UA SARS-CoV-2 COVID-19 vaccine
        VB10.COV-2 vaccine
        VBI-2900 COVID-19 vaccine
        versamune-CoV-2FC vaccine
        VLA2001 COVID-19 vaccine
        VXA-CoV2-1 vaccine
        VXA-CoV2-1.1-S vaccine
        WIBP COVID-19 vaccine
        YS-SC2-010
        ZR-202-CoV COVID-19 vaccine
        ZR202-CoV COVID-19 vaccine

Experts

1.	Wiwanitkit, Viroj: 24 articles (12/2022 - 01/2021)
2.	Talbot, H Keipp: 19 articles (07/2022 - 11/2020)
3.	Gaglani, Manjusha: 18 articles (10/2022 - 04/2021)
4.	Mungmunpuntipantip, Rujittika: 17 articles (12/2022 - 09/2021)
5.	Sheikh, Aziz: 13 articles (07/2022 - 01/2021)
6.	Naleway, Allison L: 12 articles (08/2022 - 01/2021)
7.	Thompson, Mark G: 12 articles (08/2022 - 01/2021)
8.	Li, Xue: 11 articles (12/2022 - 01/2021)
9.	Verani, Jennifer R: 11 articles (05/2022 - 05/2021)
10.	Su, John R: 11 articles (02/2022 - 03/2021)

Related Diseases

1.	COVID-19 04/29/2022 - "Our study identified several determinants of COVID-19 vaccine intention (e.g., safety, trust, risk perception, etc.) and helped to select the most relevant determinants/beliefs to target in an intervention to maximize COVID-19 vaccination uptake. " 05/23/2023 - "While SARS-CoV-2 vaccines are highly protective against severe COVID-19 disease, they do not protect against other sarbecoviruses or merbecoviruses. " 02/03/2023 - "COVID-19 vaccines are safe and highly effective in reducing severe COVID-19, hospitalizations, and mortality (7,8); nevertheless, country-reported median completed primary series coverage among adults aged ≥60 years only reached 76% by the end of 2022, substantially below the WHO goal, especially in middle- and low-income countries. " 12/02/2022 - "Currently, the most important protection against COVID-19 is the COVID-19 vaccine." 12/01/2022 - "If translated, the VIP approach could potentially offer a highly effective, long-term protection against COVID-19 for highly vulnerable populations; especially immune-deficient/senescent individuals, who fail to respond to conventional SARS-CoV-2 vaccines. "
2.	Infections 01/19/2023 - "This study confirmed the remarkable efficacy profile of the SARS-CoV-2 vaccine booster dose against infection, severe disease, and death attributable to the virus. " 06/01/2023 - "The best protection against infection is through receipt of the COVID-19 vaccine, which is associated with a low incidence of adverse events. " 01/01/2023 - "COVID-19 vaccines have dramatically reduced rates of severe infection requiring hospitalization. " 11/02/2021 - "According to short-term clinical trials, protection against infection is estimated to reach up to 95% after complete vaccination (≥14 days after receipt of all recommended COVID-19 vaccine doses). " 10/02/2023 - "In this cohort study, a booster dose of an inactivated SARS-CoV-2 vaccine provided additional moderate protection against mild infection for 120 days after receipt, but more research is needed to determine the optimal timing of a booster and its effectiveness in preventing severe infection for a longer duration."
3.	Neoplasms (Cancer) 01/01/2022 - "Our preliminary data show that the two-dose SARS-CoV-2 vaccine regimen was beneficial in all cancer patients of our study. " 09/16/2022 - "The protective effects of COVID-19 vaccines in the cancer patients presented in our study are comparable to available results of similar studies, which included the general population." 08/29/2023 - "COVID-19 vaccines in cancer patients proved safe and effective, even if efficacy may be lower than in the general population. " 01/01/2021 - "Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution." 12/15/2021 - "SIGNIFICANCE: Long-term studies of immunogenicity of SARS-CoV-2 vaccines in patients with cancer are needed to inform evidence-based guidelines for booster vaccinations and to tailor sequence and timing of vaccinations to elicit improved humoral responses."
4.	Breakthrough Infections 05/07/2022 - "COVID-19 vaccines are highly protective against severe disease; however, vaccine breakthrough infections resulting in hospitalization may still occur in a small percentage of vaccinated individuals. " 01/01/2022 - "COVID-19 vaccines prevent severe forms of the disease, but do not warrant complete protection against breakthrough infections. " 11/24/2022 - "High Anti-CoV2S Antibody Levels at Hospitalization Are Associated with Improved Survival in Patients with COVID-19 Vaccine Breakthrough Infection." 06/01/2022 - "However, the continuous emergence of SARS-CoV-2 variants, the persistence of breakthrough infections, and the seemingly rapid decline in the protective efficacy of SARS-CoV-2 vaccines have presented additional challenges for the next phase. " 02/17/2022 - "In conclusion, our results suggest that mixing different SARS-CoV-2 vaccines might lead to more efficacious and longer-lasting humoral protection against breakthrough infections."
5.	Human Influenza (Influenza) 01/01/2023 - "The influenza and COVID-19 vaccines are safe during pregnancy and are effective in reducing morbidity in both the pregnant person and infant. " 12/01/2022 - "A few have been widely used in epidemic outbreaks, including SARS and H1N1 influenza, and their use could also improve the efficacy of COVID-19 vaccines. " 06/01/2022 - "The majority believed that influenza and SARS-CoV-2 vaccines are safe and effective. " 12/01/2023 - "Despite recommendations for influenza and COVID-19 vaccines, studies have documented gaps and disparities in vaccination coverage for adults and adolescents. " 11/22/2023 - "A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study)."

Related Drugs and Biologics

1.	Vaccines
2.	Messenger RNA (mRNA)
3.	COVID-19 Vaccines
4.	BNT162 Vaccine
5.	Antibodies
6.	mRNA Vaccines
7.	2019-nCoV Vaccine mRNA-1273
8.	sinovac COVID-19 vaccine
9.	Proteins (Proteins, Gene)
10.	Immunoglobulin G (IgG)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Renal Dialysis (Hemodialysis)
4.	Immunotherapy
5.	Home Nursing (Nursing, Home)